Loading publications…
The last 5 uploaded publications
Data from Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma
Marcelo Lima Ribeiro, Diana Reyes-Garau, Meritxell Vinyoles, Núria Profitós-Pelejà, Juliana C. Santos, Marc Armengol, Miranda Fernández-Serrano, Alícia Sedó Mor, Joan Josep Bech‐Serra, Pedro Blecua, Eva Musulén, Carolina de la Torre, Hari P. Miskin, Manel Esteller, Francesc Bosch, Pablo Menéndez, Emmanuel Normant, Gaël Roué (2024). Data from Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma. , DOI: https://doi.org/10.1158/1078-0432.c.7556095.
Preprint73 days agoG protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
Marcelo Lima Ribeiro, Núria Profitós-Pelejà, Juliana C. Santos, Pedro Blecua, Diana Reyes-Garau, Marc Armengol, Miranda Fernández-Serrano, Hari P. Miskin, Francesc Bosch, Manel Esteller, Emmanuel Normant, Gaël Roué (2023). G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy. , 14, DOI: https://doi.org/10.3389/fimmu.2023.1130052.
Article73 days agoSupplementary Data from Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma
Marcelo Lima Ribeiro, Diana Reyes-Garau, Meritxell Vinyoles, Núria Profitós-Pelejà, Juliana C. Santos, Marc Armengol, Miranda Fernández-Serrano, Alícia Sedó Mor, Joan Josep Bech‐Serra, Pedro Blecua, Eva Musulén, Carolina de la Torre, Hari P. Miskin, Manel Esteller, Francesc Bosch, Pablo Menéndez, Emmanuel Normant, Gaël Roué (2024). Supplementary Data from Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma. , DOI: https://doi.org/10.1158/1078-0432.27904843.
Preprint73 days agoAntitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma
Marcelo Lima Ribeiro, Diana Reyes-Garau, Meritxell Vinyoles, Núria Profitós-Pelejà, Juliana C. Santos, Marc Armengol, Miranda Fernández-Serrano, Alícia Sedó Mor, Joan Josep Bech‐Serra, Pedro Blecua, Eva Musulén, Carolina de la Torre, Hari P. Miskin, Manel Esteller, Francesc Bosch, Pablo Menéndez, Emmanuel Normant, Gaël Roué (2021). Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma. , 27(23), DOI: https://doi.org/10.1158/1078-0432.ccr-21-1067.
Article73 days agoANTITUMORAL ACTIVITY OF THE NOVEL BTK INHIBITOR TG‐1701 IS ASSOCIATED WITH DISRUPTION OF IKAROS SIGNALING AND IMPROVEMENT OF ANTI‐CD20 THERAPY IN B‐CELL NON‐HODGKIN LYMPHOMA
Marcelo Lima Ribeiro, Diana Reyes-Garau, Meritxell Vinyoles, Núria Profitós-Pelejà, Juliana C. Santos, Marc Armengol, Miranda Fernández-Serrano, Joan Josep Bech‐Serra, Pedro Blecua, Eva Musulén, Carolina de la Torre, Hari P. Miskin, Manel Esteller, Francesc Bosch, Pablo Menéndez, Emmanuel Normant, Gaël Roué (2021). ANTITUMORAL ACTIVITY OF THE NOVEL BTK INHIBITOR TG‐1701 IS ASSOCIATED WITH DISRUPTION OF IKAROS SIGNALING AND IMPROVEMENT OF ANTI‐CD20 THERAPY IN B‐CELL NON‐HODGKIN LYMPHOMA. , 39(S2), DOI: https://doi.org/10.1002/hon.153_2880.
Article73 days ago